drugset / Trial / NCT05060432
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Phase 1/2
Unknown
153 enrolled
iTeos Therapeutics
GlaxoSmithKline · collabiTeos Therapeutics · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.
Timeline
- Start
- 2021-09-06
- Primary completion
- 2024-07
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belrestotug | Monoclonal antibody | — | — |
| Subject | Dostarlimab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | inupadenant | Small molecule | — | — |